CCDC56 Inhibitors are proposed as potential indirect inhibitors for CCDC56, targeting a variety of cellular processes and signaling pathways that could influence the function or expression of CCDC56. These inhibitors were selected based on their ability to modulate fundamental cellular mechanisms that might intersect with the yet-to-be-fully-elucidated roles of CCDC56. For example, Staurosporine, a broad-spectrum kinase inhibitor, could potentially affect kinase-mediated signaling pathways that are indirectly related to CCDC56. Similarly, Cycloheximide, by inhibiting protein synthesis, might impact the overall protein landscape in which CCDC56 operates, thereby influencing its function. MG-132 [Z-Leu- Leu-Leu-CHO], as a proteasome inhibitor, could alter the degradation of proteins that interact with or regulate CCDC56.
Inhibitors like Y-27632, free base, Rapamycin, and Brefeldin A target specific cellular processes such as ROCK-mediated cytoskeletal dynamics, mTOR signaling pathways, and Golgi apparatus function, respectively. These processes are fundamental to cellular functioning and could indirectly impact CCDC56's role in the cell. Nocodazole's effect on microtubules, SB 203580's inhibition of p38 MAPK, and LY 294002's targeting of PI3K are additional examples of how altering cellular signaling and structural dynamics can indirectly influence proteins with limited characterization. MEK inhibitors (PD 98059 and U0126) and the Hsp90 inhibitor (17-AAG) further expand the range of potential indirect influences on CCDC56. By modulating the MEK/ERK pathway and protein folding/stability, respectively, these inhibitors might affect the functional context of CCDC56 in the cell. Overall, while the direct role of CCDC56 in cellular processes remains to be fully elucidated, these proposed inhibitors offer a spectrum of tools to study its potential functions indirectly. Through the modulation of various key cellular processes and pathways, researchers can explore the functional landscape surrounding CCDC56, gaining insights into its potential roles and interactions within the cell.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
A broad-spectrum kinase inhibitor, potentially affecting kinases related to CCDC56. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
Inhibits protein synthesis, potentially impacting proteins interacting with CCDC56. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
A proteasome inhibitor, could affect protein degradation pathways related to CCDC56. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Inhibits ROCK, potentially affecting cytoskeletal dynamics related to CCDC56. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Inhibits mTOR, potentially impacting signaling pathways related to CCDC56. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Disrupts Golgi apparatus, potentially influencing processes involving CCDC56. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $59.00 $85.00 $143.00 $247.00 | 38 | |
A microtubule destabilizer, could impact cellular processes involving CCDC56. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
Inhibits p38 MAPK, potentially affecting pathways related to CCDC56. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
Inhibits PI3K, potentially influencing pathways associated with CCDC56. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
A MEK inhibitor, could indirectly affect CCDC56-related pathways. | ||||||